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Introduction
Most cancer therapies have their main mechanism of action DNA 
damage. Tumor cells have several ways to respond to this DNA damage: 
removal of the damaged area and reconstruction of the strand of DNA, 
activation of DNA damage checkpoint, changes in transcription profile 
of benefit to the cell and apoptosis in the case in which the DNA is 
seriously damaged [1,2].
We summarize in this article the most important cellular responses 
to DNA damage caused by chemotherapy.
DNA Damage
DNA damage includes both covalent and non covalent changes in 
the structure of DNA, like as base-pair mismatches, loops and bubbles 
arising from a string of mismatches.
We will see now the way in which the major chemotherapeutic 
agents induced the damage in the DNA:
Alkylating agents (eg. cyclophosphamide, nitrosoureas)
- Add methyl groups or alkyl groups to guanine.
- DNA strand cross-links (cross-links in DNA chain).
Antibiotics (eg. bleomycin, dactinomycin, doxorubicin)
- Binds to DNA, inhibits DNA replication and transcription.
- DNA strand breaks.
Inhibitors of topoisomerase I and II (eg. irinotecan, 
etoposide)
- Topoisomerase I causes a transient break in one strand of DNA 
and topoisomerase II causes breaks in the double helix, both of 
which guarantee the posterior process of DNA replication.
- Inhibition of this mechanism results in accumulation and stability 
of the topoisomerase-DNA covalent complexes and subsequently 
cell death.
Spindle poisons (eg. paclitaxel, docetaxel)
- Disrupts microtubule function.
Platinum
- Intra-strand, inter-strand DNA cross-links.
- In addition to direct damage to DNA, platinum is bound to 
proteins, altering the transmembrane transport of essential amino 
acids, the role of calcium channels, the mitochondrial respiration 
and transport of phosphate.
Antimetabolites (eg. methotrexate, pemetrexed, fluoropy-
rimidine)
- They block cell growth by interfering with DNA synthesis in S 
phase of cell cycle.
- Inhibit enzymes needed in the synthesis of nucleic acids behave 
as antagonists.
Tubulin inhibitors (eg. vincristine, vinorelbine)
- They block mitosis in metaphase. Specifically they bind to tubulin, 
inhibiting microtubule assembly and, consequently, the cell is 
in metaphase. The chromosomes are dispersed in the cytoplasm 
leading to cell death.
DNA Damage Recognition
There are three main mechanisms responsible for the recognition 
of DNA damage [3]:
1. Direct damage Recognition: it is based on the complementarity 
between a particular DNA damage and cognate protein (protein 
related individuals).
2. Multistep damage Recognition: matchmakers and combinatorial 
molecular recognition.
3. Recognition of DNA repair intermediates: DNA excision repair 
pathways damages involve removal of DNA nucleotides and 
replacement with newly synthesized DNA.
Cellular Response to DNA Damage
Depending on the attack in DNA, the cell can try to repair or 
induce apoptosis.
The main cellular responses to DNA damage are (Table 1):
Base excision repair (BER)
This system removes damaged base from DNA repair or DNA 
single strand breaks [4]. Usually non-bulky lesions are repaired by this 
system, those that do not distort the double helix structure of DNA. 
The pathway of excision repair base is the principal mechanism for 
repairing DNA alkylation and oxidative damage. Most of these injuries 
come from endogenous metabolism.
At first, a DNA glycosylase is activated after recognizing oxidized 
/ reduced bases, methylated bases, deaminated or bases mismatches. 
This DNA glycosylase breaks the bond between the glycosyl group 
and the deoxyribose-phosphate, backbone of DNA. Later apurinic 
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or apyrimidinic site is recognized by an endonuclease that produces 
a nick at site 5’ DNA. Then, a short-lyase cuts the 3’ apurinic site. 
The deoxyribose-phosphate residue is removed by an exonuclease. 
Finally, the single nucleotide gap is filled in by repair synthesis by DNA 
polymerase.
Some of the genes involved in this system are PARP1, PARP2, NEIL 
and XRCC1.
The BER mechanism is the key to maintaining the integrity of 
cellular DNA. One reason is because it is the predominant repair 
pathway for the processing of small lesions bases. It is estimated that 
about 10,000 base lesions per mammalian cell per day, and hence its 
importance. Furthermore, deletion of genes in the population BER is 
lethal to the embryo.
PARP-1 (Poly-ADP-ribose polymerase) is an enzyme that produces 
large branched chains of poly-ADP-ribose [5]. This protein senses and 
binds to DNA nicks and breaks, resulting in activation of catalytic 
activity causing poly-ADP-ribosylation of PARP-1 itself. This produces 
a recruitment of other components of DNA repair pathways. 
When PARP1, the most abundant member of the PARP family is 
inhibited, double-strand DNA breaks accumulate and under normal 
conditions are repaired via the BRCA pathway-dependent homologous 
recombination mechanism. It was thought that inhibition of PARP, in 
combination with DNA-damaging chemotherapeutics, would render 
tumors lacking BRCA function exquisitely sensitive, a hypothesis that 
has borne out in both preclinical and clinical studies. Given the shared 
clinicopathologic characteristics between BRCA-mutated and triple-
negative breast cancers, the efficacy and safety of PARP inhibition is 
being tested in both settings [6]. There are several PARP inhibitors in 
clinical development, such as iniparib, olaparib and velparib.
A phase I clinical trial with olaparib was published in 2009. 60 
patients were enrolled and treated. 22 were carriers of BRCA1 or 
BRCA2 mutations and only some of these patients had any antitumor 
response. No objective antitumor responses were observed in patients 
without known BRCA mutations [7]. 
From this study, we know that not all BRCA1 or BRCA2 carriers 
had a response to olaparib. Various BRCA1 or BRCA2 mutations may 
have resulted in differing homologous-recombination defects and 
sensitivities to PARP inhibition, or maybe differences in response 
could also have resulted from pre-existing genetic resistance.
As we have said before, triple-negative breast cancers have inherent 
defects in DNA repair. Another PARP inhibitor, iniparib, was tested 
in triple-negative breast cancer patients in a phase 2 study, comparing 
the efficacy and safety of gemcitabine and carboplatin with or without 
iniparib. In the iniparib arm the rate of clinical benefit was 56% vs. 34% 
(p=0.01) and the rate of overall response was 52% vs. 32% (p=0.02). 
The addition of iniparib also prolonged the median progression-free 
survival from 3.6 months to 5.9 months (HR 0.59; P=0.01) and the 
median overall survival from 7.7 months to 12.3 months (HR 0.57; 
P=0.01) [8].
XRCC1 interacts with most of the core components, mostly with 
DNA ligase III, polymerase beta and PARP1. It may play a role in 
DNA processing during meiogenesis and recombination in germ cells. 
Several studies have been published talking about polymorphisms in 
XRCC1 in patients treated with cisplatin, finding controversy in the 
results [9-11]. 
Although we believe that the BER pathway has a very important role 
in preserving the integrity of cellular DNA, we think that more studies 
are needed to verify the real clinical impact of the PARP inhibitors and 
to identify patients who are really likely to benefit from this treatment.
Nucleotide excision repair (NER)
This process recognized and mends DNA primarily with bulky, 
helix-distorting damage potentially capable of blocking DNA 
replication or transcription [12]. 
Damaged nucleotides are removed by the “excision nuclease”, a 
multisubunit enzyme system that makes dual incisions bracketing 
the lesion in the damaged strand. Between 24 and 32 nucleotides 
are usually removed. Subsequently, synthesis is repaired to fill the 
resulting vacuum and it is linked to the above. In humans, the NER 
system is formed by six repair factors, RPA, XPA, XPC, TFIIH, XPG 
and XPF-ERCC1 [10]. Some of them were described by mutations in 
genetic syndroms such as xeroderma pigmentosa (XPA) and Cockayne 
syndrome (CFS).
This is the most important repair system to process bulky lesions 
involving DNA distortion of the DNA strand. These lesions are formed 
by exposure to radiation or chemicals such as polycyclic aromatic 
hydrocarbons and DNA intercalating agents such as cisplatin, or 
protein adducts with DNA. The importance of NER is still emphasized 
by the fact that there are at least five genetic syndromes directly 
related to defects in this repair mechanism (xeroderma pigmentosum, 
Cockayne syndrome, trichothiodystrophy syndrome oculo-cranio-
facial-skeletal).
XP genes are involved in the recognition and repair of lesions in 
global genome NER, while CS genes play a specific role in transcription 
coupled repair [13]. 
ERCC1 is an endonuclease involved in excision of the lesion; high 
tumor tissue levels of ERCC1 mRNA in ovarian and gastric cancer have 
been associated with cisplatin resistance [14,15].
In a similar way, inhibition of ERCC1 expression has been 
associated with reduced host cell reactivation of cisplatin-treated cells 
and increased cisplatin sensitivity [16,17].
The ERCC1 expression was analysed in the International Adjuvant 
Lung Cancer Trial, demonstrating that there was a deficiency in 56% 
of the patients and was correlated with a significant improvement 
in survival following cisplatin-based chemotherapy; no benefit was 
observed in those patients with ERCC1 expression maintained [18].
Base Excision Repair (BER) PARP1, PARP2, NEIL and XRCC1
Nucleotide Excision Repair (NER) RPA, XPA, XPC, TFIIH, XPG and XPF-ERCC1
Alternative Excision Repair (AER)
Coupled Nucleotide Excision Repair 
Transcription (TC-NER) ERCC6
Mismatch Repair (MMR) MSH2 and MSH3
Translesion synthesis (TLS) DNA polymerase kappa
Nonhomologous End Joining (NHEJ) XRCC4 XRCC5
Homologous recombinational Repair 
(HRR) BRCA1, BRCA2 and RAD 51
Cell Cycle Checkpoint Control p53
Apoptosis Caspases and Bcl-2 family
Table 1: The main cellular responses to DNA damage and the principle proteins 
associated.
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In 2002 an article was published about ERCC1 mRNA expression 
in pretreatment tumor specimens from stage IV NSCLC patients 
treated with cisplatin based chemotherapy. Patients with low levels of 
ERCC1 lived 15 months in comparison with the 5 months of survival of 
patients with high levels. The response rate was higher in tumors with 
low levels of ERCC1 as well (52 vs. 36%), although this difference was 
not significant (p=0.38) [19]. 
Based on this promising clinical data, Rosell et al. published in 
2007 a phase III clinical trial of customized chemotherapy according to 
ERCC1 mRNA levels in patients with stage IV NSCLC. Patients were 
randomized in a control arm to receive cisplatin-docetaxel and in a 
genotypic arm to receive cisplatin-docetaxel if they had low ERCC1 
mRNA levels or gemcitabine plus docetaxel it they had high ERCC1 
mRNA levels. Objective response was attained by 39.3% in the control 
arm and 50.7% in the genotypic arm (P =0.02) [20].
Alternative excision repair (AER)
This is a variant of the previous two. In this case the endonuclease 
V produces a cut in only one of the damaged sites, for example, in the 
3’. This system has not been well described in humans.
Coupled nucleotide excision repair transcription (TC-NER)
This is a specialized form of NER and acts when the DNA damage 
occurs in regions that act as a template strand for transcription [21]. 
When RNA polymerase is stopped because of injury, this system moves 
beyond the damaged area and recruit repair factors, the same system as 
NER. Typically, 30 pairs of oligonucleotides are removed. The ERCC6 
is one of the genes involved in this system.
The ERCC6 protein is a DNA-binding protein which has ATP-
stimulated ATPase activity; there are contradictory publications 
reporting presence or absence of helicase activity. The protein appears 
to interact with several transcription and excision repair proteins, and 
may promote complex formation at repair sites. Single-nucleotide 
polymorphisms have been associated with overall survival in lung 
cancer [22]. 
Mismatch repair (MMR)
It recognizes and repairs base mismatches based and loops that 
form during DNA replication in mismatched nucleotides (but normal, 
i.e. not damaged). It often repairs those damages caused by oxygen 
radicals and alkylating agents. The proteins of this system may interact 
with other replication mechanisms such as BER or NER, suggesting a 
coordination of the entire process. Examples of these complex proteins 
are MSH2 and MSH3.
A complex formed by MSH2 and MSH6 recognizes mismatched 
based, recruiting MLH1 and PMS2, and then the repair is initiated 
(excision, DNA synthesis and ligation).
MMR functions as a guardian of the genome, repairing the 
mismatch without damage occurring during DNA replication. 
Although the inactivation of MMR proteins will not lead to cell death 
or other serious consequences, it greatly increases the rate of mutations 
throughout the genome due to unrepaired replication errors; this 
could initiate or promote carcinogenesis and confer a selective growth 
advantage in cells without MMR.
Defective in mismatch repair is known as microsatellite instability 
(MSI); a majority of cancers derived from patients with hereditary 
non-polyposic colorectal cancer (HNPCC) presents mutations in 
mismatch repair. Nearly of 85% of them have mutations in MLH1 or 
MSH2. A 15% of sporadic colon cancer is also related with mutations 
in mismatch repair.
Many but not all tumors that contain MMR mutations can be 
identified by the presence of a high degree of MSI (MSI-H). The majority 
of patients with HNPCC have MSI-H tumors. Most laboratories use 
a panel of several microsatellite loci when testing for MSI. A panel 
consisting of three dinucleotide repeats and two mononucleotide 
repeats have been proposed as a standard test for MSI; a tumor is called 
MSI-H when at least two (40%) are affected by instability. While almost 
all MSI-H tumors are MMR deficient, most MSI-L tumors have no 
MMR defect.
The MSI-L phenotype has been associated with methylation 
of the promoter for the DNA repair gene 0-6methylguanine DNA 
methyltransferase (MGMT). It has been hypothesized that loss 
of expression of MGMT results in accumulation of methyl G:T 
mismatches and excess stress on the mismatch repair system, which 
ultimately leads to MSI-L. Being rare in HNPCC, MGMT methylation 
of loss or MGMT expression occurs in up to 25% of sessile serrated 
adenomas, 78% of dysplastic serrated adenomas, and 50% of serrated 
adenocarcinomas. These findings suggest that the factors leading to the 
MSI-l phenotype may be important in the serrated neoplasia pathway.
As we have said before, mutations and allelic loss of one of the 
MMR genes are responsible for the MSI phenotype in most cases of 
HNPCC. However, hypermethylation of the promoter region of some 
MMR genes and/or DNA hypomethylation with loss of imprinting 
is thought to underlie cases of sporadic CRC that display the MSI 
phenotype. 
DNA hypermethylation specifically targets CpG dinucleotides, 
which are present in the promoters of many genes (including 
the MMRgene hMLH1). Although the stimulus that drives 
hypermethylation remains unknown, methylated CpG is bound by a 
family of proteins known as methyl-CpG binding domain proteins. 
These proteins form a multiprotein complex that alters chromatin 
conformation and silences gene expression.
A potential resistance to 5-fluorouracil chemotherapy has been 
described with mutations in mismatch repair. 
The immunohistochemical expression of MSH2 has also been 
studied as a predictive factor in patients with lung cancer treated with 
surgery and platinum-based adjuvant chemotherapy. In a sub analysis 
of the International Adjuvant Lung Cancer Trial it was determined the 
expression of MSH2 in 673 patients. MSH levels were low in 38% of 
cases and high in 62%, there was a tendency to prolong overall survival 
in patients treated with chemotherapy and low MSH2 expression (p 
<0.03), but not when your expression was high. Furthermore, when 
combined the analysis taking into account the expression of MSH2 
and ERCC1, the benefit of chemotherapy was lower as they expressed 
greater amounts of these markers. Chemotherapy prolongs overall 
survival in the subgroup of patients with low MSH2 / low ERCC1 (HR, 
0.65, 95% CI, 0.47 to 0.91, P = 0.01 [23].
Translesion synthesis (TLS)
It is a damage tolerance mechanism, allowing replication to 
continue despite the damage by a DNA polymerase or more than one. 
The correct base is inserted opposite the lesion during the formation of 
the daughter strand, belongs to the complex POLI POLK.
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DNA polymerase kappa (POLkappa) is frequently overexpressed 
in human lung cancer tissues. It is also described as an association 
between elevated expression and p53 inactivation in lung cancer tissues.
Nonhomologous end joining (NHEJ)
It is responsible for repairing double-stranded DNA when it 
breaks. This repair mechanism occurs in mammalian cells when the 
DNA damage is out of replication fork and not in S-phase. It rejoins the 
broken ends, free of DNA, and often involves loss of a DNA sequence 
in free DNA ends. To ensure accurate repair, this system is based on 
short homologous sequences called micro homologies, present in 
single-stranded tails at the ends of DNA that must be joined. If these 
sequences are compatible, repair is usually correct. XRCC4 XRCC5 
mutations and this system in XRCC4 are associated with embryonic 
lethality in mice specimens. This can be mitigated by crossing the 
XRCC4 knockouts with p53 mutants, suggesting that lethality is a result 
of p53 mediated apoptosis. Some polymorphisms of XRCC4 have been 
described related to high risk of lung cancer, colon cancer and thyroid 
[24-26].
Homologous recombinational repair (HRR)
It repairs double-stranded DNA replication fork and when cells are 
in S phase. It requires the presence of an identical or nearly identical 
sequence to be used as a template to repair the tear. This system allows 
that a damage chromosome is repaired using a sister chromatid 
(available in G2 phase after DNA replication) or homologous 
chromosome as a template. This system can be further subdivided into 
the gene conversion and single-strand annealing subpathways.
Examples of proteins belonging to this system are BRCA1, BRCA2 
and RAD 51.
The BRCA1 gene is located on chromosome 17 (17q21). More 
than two hundred mutations have been identified in the BRCA1 
gene. Depending on the mutation, an abnormally short version of the 
BRCA1 protein is found, or any protein is made from one copy of the 
gene. Other BRCA1 mutations change single protein building blocks 
(amino acids) in the protein or delete large segments of DNA from the 
BRCA1 gene. It is thought that a defective or missing BRCA1 protein 
is unable to repair damaged DNA or fix mutations that occur in other 
genes, which is the main cause of its association with increased cancer 
risk (particularly breast cancer and ovarian cancer).
BRCA1 and BRCA2-deficient cells are highly sensitive to ionizing 
radiation and display chromosomal instability, which is likely to be a 
direct consequence of unrepaired DNA damage. 
BRCA1 has a role in signalling DNA damage and cell-cycle 
checkpoint regulation; however BRCA2 has a more direct role in DNA 
repair itself [3]. It is thought that BRCA2 promotes genomic stability 
through a role in the error-free repair of double-strand breaks.
The interaction of BRCA1, BRCA2 and RAD51 suggest a functional 
link between the three proteins. The physical interaction between 
BRCA2 and RAD51 is essential for error-free double-strand breaks. 
BRCA2 is required for the localization of RAD51 to sites of DNA 
damage, where RAD51 forms the nucleoprotein filament required for 
recombination [3]. 
There are more than 600 mutations in the BRCA1 gene, many of 
which are associated with an increased risk of cancer. Hypermethylation 
of its promoter has been associated with the development of breast 
cancer, which is believed to be understood as a mechanism to inactivate 
the expression of BRCA1.
In BRCA1 but not BRCA2 associated tumors, additional molecular 
genetic abnormalities that are commonly found include mutations in 
p53 and PTEN tumor suppressor genes.
Data also suggest a potential role of BRCA1 and BRCA2 mutations 
in sporadic breast and ovarian cancers, in particular triple-negative, or 
medullary histology. The genomic instability of BRCA1 and 2 deficient 
cells in hereditary and triple-negative breast cancer provide an 
opportunity for therapeutic development, especially drugs that target 
DNA repair pathways. This includes platinum-type drugs that generate 
double-stranded DNA breaks or PARP inhibitors, which are involved 
in the repair of DNA single-strand breaks.
The population frequency of mutations in the BRCA1 and 2 genes 
is generally estimated to be 1/800 to 1/1000 per gene [27]. Higher 
prevalence is found among individuals with a personal history of breast 
cancer and/or a family history of breast and ovarian cancer, especially if 
associated with young age on onset, multiple tumors, and involvement 
of male family members affected with breast cancer.
Cancer syndrome hereditary breast and ovarian cancer due to 
BRCA1 and 2 mutations in the germ line, with an autosomal dominant 
inheritance pattern is characterized by a high risk of breast cancer, 
between 50 and 85%, and 15-40% of ovarian cancer. Individuals 
suspected of having a hereditary predisposition to breast and/or ovarian 
cancer based upon personal and family history should be referred to a 
genetic counsellor for formal risk assessment.
These last two mechanisms, homologous recombination and 
nonhomologous are extremely crucial for maintaining cell survival, 
proliferation and genomic stability. The breaking of the double strands 
of DNA (DSB), substrate of both mechanisms is the most lethal DNA 
lesions, and appears with a high frequency. Although it appears that 
cells can tolerate a small amount of irreparable DNA damage, a single 
break in the double-stranded DNA can be cytotoxic or in some cases 
sufficient to trigger apoptosis; also it has been established as a causal 
link between DSB and genomic instability. As noted previously, it has 
been shown that defects in both pathways lead to cancer.
Cell cycle checkpoint control
This system delays the cell cycle progression in response to DNA 
damage for the cell to have a half “extra” and try to repair the damage 
before entering a critical phase that can become lethal. P53 belongs to 
this system.
The p53 gene is located on the short arm of chromosome 17 
(17p13), is essential to induce cell response to DNA damage, arresting 
the cell cycle in case of mutation [28].
The transcription factor p53 has several important functions:
a) Cell cycle arrest in G1 / S transition: it is due to p53-dependent 
transcription of the CDK inhibitor called CDKN1A/p21; p21 
inhibits CDK-cyclin complexes and prevents the phosphorylation 
of pRb, so that the factor inactivates E2F transcription and 
prevents the progression of the cell into S phase. Thus, the cell has 
time to repair the damage to DNA.
b) Activation of DNA repair enzymes: a transcriptional target 
genes, p53R2 encodes a ribonucleotide reductase, important for 
DNA replication and repair. Likewise, it also interacts directly 
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with AP endonuclease and DNA polymerase involved in excision 
repair. P53 protein also induces GADD45 (growth arrest and 
DNA damage), which helps repair DNA. If the damage is fully 
repaired, p53 stimulates the synthesis of Mdm2, activating its self-
destruction and cell cycle progression, but if the cell is not able to 
repair the damage, apoptosis or senescence enter both processes 
induced by p53.
c) Entry into apoptosis: P53 activates the expression of genes such 
as BAX pro-apoptotic or PUMA. The process of how the cell 
“chooses” to repair their DNA or enter apoptosis is not entirely 
clear, it appears that p53 has higher affinity for the promoters 
of DNA repair genes than pro-apoptotic genes. Thus, p53 levels 
would be crucial to this. At first trigger DNA repair, but if this is 
ineffective and p53 levels continue to rise, it would activate pro-
apoptotic genes.
d) Entry into senescence: This is a permanent stop in the cell cycle 
usually irreversible. The changes are not yet fully known, but appear 
to involve epigenetic chromatin modifications as heterocromatina 
training block in the proliferation activating genes regulated by 
E2F. The entry into senescence can be induced by the presence of 
different types of stress such as hypoxia, telomere shortening or 
oncogenic signaling.
It is vital to the strong regulation of the cellular concentration of 
p53, because even if p53 is a tumor suppressor, high levels can accelerate 
the aging process by excessive apoptosis. Its main regulator is Mdm2, 
which can activate p53 degradation by ubiquitination.
p53 is able to detect the presence of cell damage, but  two key sensors 
of DNA damage are two related kinases: ATM (ataxia telangiectasia 
mutated) and ATR (ataxia telangiectasia and RAD3 related); they were 
initially identified in patients with ataxia-telangiectasia, which have a 
high incidence of cancer as they are not able to repair certain DNA 
lesions. They detect different types of lesions in the DNA, but they 
activate similar signaling pathways, phosphorylates several proteins 
involved in DNA repair and p53. When p53 is phosphorylated, it is 
released from its association with Mdm2, acting as a transcription 
factor and increasing the expression of proteins such as GADD45 (DNA 
repair), p21 (inhibition of progression through the cell cycle) and BAX 
(promotion of apoptosis). Likewise, p53 activates transcription of the 
family of mir34 microRNAs, small RNA molecules that prevent the 
translation of specific mRNAs, inducing major stop on the cell cycle 
and apoptosis.
Mutations in p53 are presents in more than 50% of the global of 
the tumors.
P53 mutations have been associated with lung cancer more often 
than any other genetic abnormality. Rates of detected mutations 
range from 20 to 60 percent of all cases of NSCLC, and they are more 
common in cancers associated with smoking, such as SCC, compared to 
adenocarcinomas. Loss of heterozygosity (deletion of genetic material 
from one 17p allele) also occurs in the bronchial tissue of approximately 
20 percent of smokers, possibly identifying a population at high risk 
for developing malignancy. Particularly, specific hotspot mutations in 
p53 that result in substitution of thymidine for guanine residues are 
commonly seen in smoking-induced cancers. The relationship between 
p53 mutations and survival in patients with NSCLC remains unclear 
despite years of study. At least two meta-analyses have explored the 
influence of p53 mutations or over expression on prognosis. In the 
first one, the authors suggests that an abnormal p53 status had an 
unfavourable impact on survival in any stage NSCLC, but in the second, 
the negative prognostic impact of p53 alteration was highly significant 
in patients with adenocarcinoma but not in those with SCC.
Most of these studies are retrospective, limited by small size, 
with heterogeneous populations and with insensitive p53 mutation 
detection techniques. It is also important that reported concordance 
levels between immunohistochemistry and mutational analysis for p53 
mutations are only approximately 65%. Certain p53 mutations may 
result in either no p53 expression or low levels of expression that are 
not detectable by IHC. Bodner et al. published an article in which less 
than one-half of gene mutations were associated with a positive IHC 
p53 protein.
It is also described as a relationship between aberrant p53 
expression and angiogenesis in patients with NSCLC.
Different tumors with a high percentage of p53 mutations are 
colorectal cancer, ovarian cancer, secondary glioblastoma, non-
melanoma skin and head and neck.
Apoptosis
It is programmed cell death or “cell suicide”. It starts as a result 
of severe damage in DNA that prevents the cell to perform its normal 
functions. It may begin in the final third of G1 (to prevent a damaged 
cell to S phase pass, so that mutations may not play during DNA 
replication) and G2 phase (to prevent cells that have not reached to 
maturity enter mitosis). Apoptosis occurs by chromatin condensation, 
cytoplasmic shrinkage, plasma membrane blebbing and the division of 
DNA. In this mechanism, several agents act to highlight the complex 
cysteinyl-aspartate proteases (caspases) and Bcl-2 family.
Apoptosis in mammalian cells is mediated by a family of 
cysteine  proteases, caspases. These proteins are present in cells in an 
inactive form, when the initiator caspases (8 and 9) are activated by 
oligomerization, the proto-digested effector caspases (3, 6 and 7), 
activating them. The active effector caspases digest a specific group of 
cellular substrates, which regulate the orderly destruction of the cell. 
Subsequently, cell membranes are broken, cytoplasm and cytoskeleton 
collapse, the cytosol is consumed, the chromosomes are degraded and 
the nucleus is fragmented.
Apoptosis can be triggered by various mechanisms, both internal 
(DNA damage, mediated by p53 signaling imbalance, insufficient 
growth factors or hypoxia, HIF-mediated) and external (physical 
or chemical agents). And so, one of the two pathways that control 
apoptosis is activated:
- The extrinsic pathway is activated by the binding of different 
signals to the membrane receptors of the superfamily of receptors 
for tumor necrosis factor, and Fas. This pathway is used by 
cytotoxic T lymphocytes, which present on their surface Fas ligand 
to induce apoptosis in certain cells.
- The intrinsic pathway or mitochondrial involves permeabilization 
of the outer mitochondrial membrane, allowing cytoplasmic 
release of cytochrome c. This pathway is controlled by proteins of 
the Bcl-2 family.
Bcl-2 is a family of proteins anti-apoptotic made  up of about 25 
proteins that regulate mitochondrial permeabilization processes [29]; 
they are a key point in the intrinsic pathway of apoptosis. Its name 
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comes from the proto-oncogene Bcl-2 (B-cell lymphoma 2), a member 
of a group of proteins described in studies of the translocation between 
chromosomes 14 and 18 observed in follicular lymphomas. Further 
investigation described the existence of two homologous pro-apoptotic 
subfamilies, Bax and BH3.
In viable cells, BAX and BAK (both family proteins BAX, 
proapoptotic) are in monomeric form [30], the first anchored to 
the cytosolic face of various organelles and the second within the 
mitochondria. Before a cell death signal, BAX is inserted into the 
outer membrane of mitochondria as homooligomer and BAK 
undergoes a conformational change that includes its oligomerization 
and permeabilization of the mitochondrial outer membrane with 
the release of intermembrane space factors such as cytochrome c. 
Cytochrome c, once in the cytosol, it activates a protein complex called 
“apoptosome”, which directly activates caspase-9. Once caspase-9 is 
activated, it activates the effector caspases such as caspase-3, triggering 
the final stages of apoptosis. This process occurs equally in mediating 
the endoplasmic reticulum calcium release.
The BH3 subfamily members function as initiators of the pathway 
that selectively integrate the various specific responses death and 
survival.
Bcl-2 is highly expressed in neoplastic cells in over 90% of follicular 
lymphoma patients [31]. This high expression of Bcl2 is due to a specific 
chromosomal translocation t (14;18) (q32;21) that generates a fusion 
between the immunoglobulin heavy chain enhancer on chromosome 
14 and the Bcl-2 gene on chromosome 18; this was one of the earliest 
chromosomal translocations related to cancer development to be 
discovered. Normally, most B-cells should be terminated via apoptosis 
if they are not challenged by specific antigens. With the overexpression 
of Bcl-2, follicular lymphoma cells are able to overcome normal 
apoptotic signals and avoid termination. Therefore, the prolonged 
life span of follicular cells due to this defect in apoptotic elimination 
contributes to the development of follicular lymphoma.
Bcl-2 family, other than in the follicular B-cell lymphoma, is involved 
in a number of cancers, including melanoma and breast carcinoma, 
prostate and lung. Its expression was associated with good prognosis 
in non-small-cell lung cancer. Cytotoxicity of many chemotherapeutic 
agents is induced through the Bcl-2 apoptotic pathway; overexpression 
of BCL2 is associated with increased resistance to these agents.
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